NTLA
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) has 10 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 24, 2026.
Insiders have net sold $220K over the trailing 6 months.
- Industry:Biotechnology
- CEO:John Leonard
- Employees:403
- HQ:Cambridge, MA, US
- IPO:2016-05-06
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$220K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$1.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP, Chief Financial Officer | Sale | 8,111 | $91K | Jul 24 | SEC ↗ | |
Dulac Edward J IIIFirst filing | EVP, Chief Financial Officer | Sale | 4,677 | $84K | Jul 6 | SEC ↗ |
Dube Michael PFirst filing | VP, Chief Accounting Officer | Sale | 2,641 | $44K | Jul 6 | SEC ↗ |
Related companies
Intellia Therapeutics, Inc. is in the Healthcare sector.